In this article, we discuss the top 5 stocks in Viking Global’s portfolio. If you want our detailed analysis of these stocks, go directly to Viking Global’s Top 10 Stocks.
5. Humana Inc. (NYSE:HUM)
Percentage of Viking Global’s 13F Portfolio: 3.24%
Viking Global’s Stake Value: $1,170,226,000
Number of Hedge Fund Holders: 7
Humana Inc. (NYSE:HUM), a health insurance company, is one of the top stocks in Viking Global’s portfolio. Between June and September last year, the hedge fund increased its stake in the Kentucky-based Medicare program provider by 412%. At the end of Q3, Viking Global had a stake worth $1.2 billion in Humana Inc. (NYSE:HUM).
On the second week of February, Humana Inc. (NYSE:HUM) stock gained 11% after the Centers for Medicare & Medicaid Services (CMS) announced a proposed increase in Medicare rates in 2023. Recently, the health insurance firm reported its Q4 earnings, which fell short of revenue expectations, but overall sales grew 10.4% to $21.05 billion in the fourth quarter of 2021. Following strong Q4 results, investment banking firm Deutsche Bank increased its price target for Humana Inc. (NYSE:HUM) to $435 from $418 while maintaining a Hold rating on the shares.
At the end of the third quarter of 2021, 60 elite funds tracked by Insider Monkey had a total stake of $2.9 billion in Humana Inc. (NYSE:HUM), up from 59 hedge funds in Q2 with a total stake of $3.26 billion.
4. BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Percentage of Viking Global’s 13F Portfolio: 3.46%
Viking Global’s Stake Value: $1,247,726,000
Number of Hedge Fund Holders: 28
BridgeBio Pharma, Inc. (NASDAQ:BBIO), a California-based biotech company, is one of the top stocks sitting in Viking Global’s portfolio since the second quarter of 2019. In Q3 2021, Viking Global held the largest stake in the company, worth $1.25 billion.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) markets two FDA-approved rare genetic disease therapies namely Nulibry and Truseltiq. In addition, the biopharmaceutical firm is working on 30 gene therapy pipelines that could potentially treat muscle dystrophies, cardiorenal syndromes, and cancer.
As per Insider Monkey’s Q3 data, the number of hedge funds holding stakes in BridgeBio Pharma, Inc. (NASDAQ:BBIO) stood at 28 in Q3, compared with 27 in the previous quarter.
In the Q2 2021 investor letter, Baron Opportunity Fund highlighted a few stocks, and Bridgebio Pharma Inc. (NASDAQ:BBIO) is one of them. Here is what the fund said:
“BridgeBio Pharma, Inc. is a biotechnology company developing drugs that address a host of genetic disorders. Shares fell in the quarter given concerns around increasing competition. While we expect positive results from BridgeBio’s Phase 3 trial for its lead program for TTR amyloidosis, a disease in which toxic proteins build up in the heart and nerves, encouraging updates from Alnylam’s competing drug, Vitrusiran, and more recently, Intellia’s gene editing platform, pressured the stock. We exited our position.”
3. T-Mobile US, Inc. (NYSE:TMUS)
Percentage of Viking Global’s 13F Portfolio: 3.62%
Viking Global’s Stake Value: $1,306,370,000
Number of Hedge Fund Holders: 89
Shares of T-Mobile US, Inc. (NYSE:TMUS) jumped 11% following its solid Q4 earnings report. On February 3, RBC Capital set a new price target of $152 for the telecom stock and maintained an Outperform rating on the shares.
In Q3 2021, Viking Global increased its stake by 36% in T-Mobile US, Inc. (NYSE:TMUS). The hedge fund held shares worth over $1.3 billion in the company, which represented 3.62% of its 13F portfolio. In total, 89 hedge funds were long T-Mobile US, Inc. (NYSE:TMUS) at the end of September 2021, compared to 100 in the preceding quarter.
Aside from Viking Global, Warren Buffett’s Berkshire Hathaway is among the largest shareholders in T-Mobile US, Inc. (NYSE:TMUS). In Q3, the fund held 5.24 million shares of the telecom company worth nearly $670 million.
2. General Electric Company (NYSE:GE)
Percentage of Viking Global’s 13F Portfolio: 4.83%
Viking Global’s Stake Value: $1,743,649,000
Number of Hedge Fund Holders: 53
High-tech industrial firm General Electric Company (NYSE:GE) is one of the newly added positions in Viking Global’s portfolio in Q3 2021. The hedge fund bought 16.9 million shares of General Electric Company (NYSE:GE) valued at $1.74 billion.
General Electric Company (NYSE:GE), one of the world’s leading industrial companies, is known for producing electrical and electronic equipment, medical devices, aircraft engines, and renewable energy solutions. The company announced total orders amounting to $22.1 billion for the fourth quarter of 2021, fueled by increased orders in the aviation and healthcare segments, which contributed $7.7 billion and $5.3 billion, respectively.
In January, Deutsche Bank maintained a Buy rating on General Electric Company (NYSE:GE) and set a new price target of $108 for the industrial stock. Meanwhile, there were 53 hedge funds that held stakes in General Electric Company (NYSE:GE) at the end of September 2021. The total value of this stake is $6.24 billion.
Here is what Vulcan Value Partners has to say about General Electric Company in its Q3 2021 investor letter:
“During the quarter, we sold our positions in General Electric Co. General Electric is a company we followed for a long time. In the past, we removed GE from the MVP list due to management’s poor capital allocation decisions which resulted in value instability. Larry Culp, the former CEO of Danaher, became CEO of General Electric in 2018. The company implemented a vast restructuring program to simplify the industrial side of its business, sold off non-core assets, paid down debt with the proceeds, and drastically shrunk GE Capital. These restructuring activities allowed its world-class jet engine and healthcare businesses to shine through, and improved value stability. As a result, we added the company back to the MVP list. While the pandemic negatively impacted General Electric’s aviation business in the short run, it also gave us the opportunity to buy General Electric in the second quarter of 2020 with a substantial margin of safety. GE is a good example of a competitively entrenched, yet slower-growing MVP business. As its stock price rose rapidly over the last year, its value growth did not keep up, and the price to value gap closed quickly. As our margin of safety diminished, we sold our position in GE and allocated to more discounted companies.”
1. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Percentage of Viking Global’s 13F Portfolio: 9.74%
Viking Global’s Stake Value: $3,511,109,000
Number of Hedge Fund Holders: 32
Cell engineering company Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is the biggest holding in Viking Global’s portfolio as of Q3 2021. The Boston-based biotech firm focuses on developing cell programming platforms that are utilized in manufacturing applications from cheesemaking to pharmaceuticals. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) also provides COVID-19 monitoring services, with over 3 million tests accomplished in the second half of 2021.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) purchased Project Beacon COVID-19 LLC, a COVID-19 testing provider, in January to reinforce its expanding biosecurity platform and provide broader COVID-19 testing options in Massachusetts.
Viking Global initiated its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) in Q3 2021 and purchased over 302 million shares worth more than $3.5 billion. The company represents 9.74% of Viking Global’s 13F holdings at the end of September 2021.
Moreover, 32 hedge funds were bullish on Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) at the end of the third quarter of 2021.
You can also take a look at the Top 10 Stock Picks of Travis Cocke’s Voss Capital and 15 Blue Chip Dividend Stocks With Over 4% Yield.
